Cart is empty 
Overview
PT-141, also known as Bremelanotide, is a synthetic melanocortin receptor agonist derived from Melanotan II. Research has focused on melanocortin signaling, neuroendocrine regulation, central nervous system pathways, behavioral neuroscience, and receptor pharmacology. Unlike many metabolic peptides, PT-141 primarily acts through central melanocortin pathways rather than peripheral vascular mechanisms.
Mechanism of Action
Research suggests PT-141 acts as an agonist primarily at melanocortin receptors MC3R and MC4R within the central nervous system. Activation of these receptors influences neuroendocrine signaling, neurotransmitter activity, and behavioral pathways. Studies have investigated its effects on hypothalamic signaling, autonomic regulation, and melanocortin-mediated neurological responses.
Compound Information
Stability Information
- Type: Synthetic Melanocortin Receptor Agonist
- Parent Compound: Melanotan II Derivative
- Molecular Formula: C50H68N14O10
- Molecular Weight: 1025.2 g/mol
- Research Areas: Neuroendocrinology, melanocortin signaling, receptor pharmacology
- Room temperature stable (short-term)
- Protect from light
- Avoid repeated freeze-thaw cycles
- Lyophilized: Store at -20°C
- Reconstituted: Store at 2-8°C
Published Studies
- Bremelanotide for treatment of female sexual dysfunction
- Melanocortin receptor agonists and neuroendocrine regulation.
- Pharmacology of Bremelanotide and melanocortin receptors
- Melanocortin signaling in the central nervous system.
- Clinical development of Bremelanotide.
- MC4 receptor activation and neurobehavioral signaling pathways.
- Melanocortin receptor agonists in neuroscience research.
- Bremelanotide and hypothalamic melanocortin pathways.
- Structure and activity relationships of melanocortin agonists.
- Melanocortin receptor pharmacology and peptide therapeutics.
Information provided for educational and research reference purposes only. Studies listed are third-party publications and do not constitute medical advice.